Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine PK and DDI study with Itraconazole
NCT02824042Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of anetumab ravtansine in pleural mesothelioma, peritoneal mesothelioma, ovarian cancer and 7 more, sponsored by Bayer. Primary endpoints: PR interval duration up to 2 months, QRS interval duration up to 2 months and 6 more. Started Sep 2016; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
pleural mesotheliomaperitoneal mesotheliomaovarian cancerpancreatic adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02824042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824042.